体育运动和脂质代谢

一般健康人总胆固醇(T-Ch)、甘油三酯(TG)、高密度和低密度脂蛋白胆固醇(HDL-ch,LDL-cH)的含量随年令而增加。中年组(45-59)HDL-Ch平均值较低,男比女低,这与中国人男性45岁以后患冠心病(CHD)多于女性相吻合。冠心病及脑中风患者的HDL-ch含量比健康人低(P<0.05)。运动员的HDL-Ch含量明显高于一般健康人(P<0.01),其均值且高于不易患动脉粥样硬化(AS)的八种哺乳动物的均值(60.40mg/d1)。运动员的T-ch、TG和HDL-Ch含量低于健康人。     

运动负荷对青年学生和运动员心脏功能的影响

用无创法(阻抗法)测量了40名青年学生和40名运动员在两种运动负荷(50W和150W)运动前、运动后即刻和恢复时程的收缩时间间期(STI)和心率(HR)。在静态时,“运动员组”的心率较缓(P<0.01)、QS_1较长(P<0.05)、PEP/LVET比值较大(P<0.05和P<0.01)、LVETc较短(P<0.001)。运动后即刻,“学生组”和“运动员组”都表现为QS_z、LVET、PEP、IVCT、QS_1缩短、PEP/LVET比值减小、心率增速和LVETc延长。但“运动员组”QS_2、LYET的缩短和心率增速的程度较少,而PEP/LVET比值的减小和LVETc延长的程度较大。除PEP/LVET比值外,其余各项指标的恢复速度均与负荷量有关。“运动员组”的恢复速度较快,尤其在150W时更为明显。本文指出:1)用阻抗法测算动态下的STI更为实用;2)系统训练可提高心脏活动的潜力,改善泵功能,促进心脏活动的调节速度。     

Circadian Rhythm and Seasonal Variations in Basal cAMP Content of Rat Heart Ventricles

The cAMP content in rat heart ventricles was studied at 3-hr intervals during 24hr at different times of the year. A significant circadian rhythm in cAMP content was found. Time of the year reproducibly influenced the 24-hr mean, the amplitude as well as the peak value in cAMP in relation to circadian time.     

Does the dysregulation of matrix metalloproteinases contribute to recurrent implantation failure?

Introduction: The progress in in vitro fertilization (IVF) techniques for infertility management has led to the investigation of embryo implantation site proteins such as Matrix metalloproteinases (MMPs), which may have a key role in embryo-endometrium crosstalk and in the molecular mechanisms of the embryo implantation.

Areas covered: Numerous studies have generated much information concerning the relation between the different proteins at the site of implantation such as cytokines, growth factors, adhesion molecules and MMPs. However, the exact role of the MMPs in embryo implantation and the impact of their dysregulation in recurrent implantation failure have yet to be characterized.

Expert commentary: The proteomic investigation of the MMPs and their molecular pathways may enable scientists and clinicians to correct this dysregulation (via appropriate means of prevention and treatment), better manage embryo transfer during IVF cycles, and thus increase the ongoing pregnancy rate.     

Molecular mechanism and therapy application of necrosis during myocardial injury

Necrosis is an ancient topic which gains new attraction in the research area these years. There is no doubt that some necrosis can be regulated by genetic manipulation other than an accidental cell death resulting from physical or chemical stimuli. Recent advances in the molecular mechanism underlying the programmed necrosis show a fine regulation network which indicates new therapy targets in human diseases. Heart diseases seriously endanger our health and have high fatality rates in the patients. Cell death of cardiac myocytes is believed to be critical in the pathogenesis of heart diseases. Although necrosis is likely to play a more important role in cardiac cell death than apoptosis, apoptosis has been paid much attention in the past 30 years because it used to be considered as the only form of programmed cell death. However, recent findings of programmed necrosis and the related signalling pathways have broadened our horizon in the field of programmed cell death and promote new pharmacological application in the treatment of heart diseases. In this review, we summarize the advanced progress in these signalling pathways and discuss the pathos‐physiological relevance and therapeutic implication of targeting necrosis in heart diseases treatment.     

The anatomical components of the cardiac outflow tract of chondrichthyans and actinopterygians

The outflow tract of the fish heart is the segment interposed between the ventricle and the ventral aorta. It holds the valves that prevent blood backflow from the gill vasculature to the ventricle. The anatomical composition, histological structure and evolutionary changes in the fish cardiac outflow tract have been under discussion for nearly two centuries and are still subject to debate. This paper offers a brief historical review of the main conceptions about the cardiac outflow tract components of chondrichthyans (cartilaginous fish) and actinopterygians (ray‐finned fish) which have been put forward since the beginning of the nineteenth century up to the current day. We focus on the evolutionary origin of the outflow tract components and the changes to which they have been subject in the major extant groups of chondrichthyans and actinopterygians. In addition, an attempt is made to infer the primitive anatomical design of the heart of the gnathostomes (jawed vertebrates). Finally, several areas of further investigation are suggested. Recent work on fish heart morphology has shown that the cardiac outflow tract of chondrichthyans does not consist exclusively of the myocardial conus arteriosus as classically thought. A conus arteriosus and a bulbus arteriosus, devoid of myocardium and mainly composed of elastin and smooth muscle, are usually present in cartilaginous and ray‐finned fish. This is consistent with the suggestion that both components coexisted from the onset of the gnathostome radiation. There is evidence that the conus arteriosus appeared in the agnathans. By contrast, the evolutionary origin of the bulbus is still unclear. It is almost certain that in all fish, both the conus and bulbus develop from the embryonic second heart field. We suggest herein that the primitive anatomical heart of the jawed vertebrates consisted of a sinus venosus containing the pacemaker tissue, an atrium possessing trabeculated myocardium, an atrioventricular region with compact myocardium which supported the atrioventricular valves, a ventricle composed of mixed myocardium, and an outflow tract consisting of a conus arteriosus, with compact myocardium in its wall and valves at its luminal side, and a non‐myocardial bulbus arteriosus that connected the conus with the ventral aorta. Chondrichthyans have retained this basic anatomical design of the heart. In actinopterygians, the heart has been subject to notable changes during evolution. Among them, the following two should be highlighted: (i) a decrease in size of the conus in combination with a remarkable development of the bulbus, especially in teleosts; and (ii) loss of the myocardial compact layer of the ventricle in many teleost species.     

Regulation of circulating chromogranin B levels in heart failure

Background: Chromogranin B (CGB) regulates B-type natriuretic peptide (BNP) production. Circulating CGB levels are elevated in heart failure (HF) animal models and HF patients, but also increase in healthy individuals in response to physical activity. Therefore, CGB seems to integrate information from myocardial stress and systemic neuro-endocrine activation. Substantial gaps remain in our understanding of CGB regulation in HF.

Methods and results: We conducted a retrospective registry study including 372 patients. CGB and N-terminal pro-BNP (NT-proBNP) plasma levels were assessed in acute HF and chronic valvular HF patients and controls. CGB levels were significantly increased in acute HF and chronic valvular HF, but significantly higher in the latter. Patients in chronic valvular HF with severe mitral regurgitation (cHF-MR) showed significantly higher CGB levels than patients in chronic valvular HF with severe aortic stenosis. CGB levels progressively increased with worsening NYHA functional status and were moderately correlated to NT-proBNP, but independent of left ventricular (LV) ejection fraction (LVEF), LV mass, age and body weight. Finally, cHF-MR patients showed significant reductions of CGB levels after interventional mitral valve repair.

Conclusion: CGB is a promising emerging biomarker in HF patients with unique potential to integrate information from myocardial stress and neuro-endocrine activation.     

NTproBNP and ST2 as predictors for all-cause and cardiovascular mortality in elderly patients with symptoms suggestive for heart failure

Background: A new biomarker, suppression of tumorigenicity 2 (ST2) has been introduced as a marker for fibrosis and hypertrophy. Its clinical value in comparison with N-terminal pro-hormone of brain natriuretic peptide /Amino-terminal pro-B-type natriuretic peptide (NTproBNP) in predicting mortality in elderly patients with symptoms of heart failure (HF) is still unclear.

Aim: To evaluate the prognostic value for all-cause- and cardiovascular mortality of ST2 or NTproBNP and the combination of these biomarkers.

Patients and methods: One hundred seventy patients patients with clinical symptoms of HF (77 (45%) were with verified HF) were recruited from one selected primary health care center (PHC) in Sweden and echocardiography was performed in all patients. Blood samples were obtained from 159 patients and stored frozen at –70?°C. NTproBNP was analyzed at a central core laboratory using a clinically available immunoassay.ST2 was analyzed with Critical Diagnostics Presage ST2 ELISA immunoassay.

Results: We studied 159 patients (mean age 77?±?8.3?years, 70% women). During ten years of follow up 78 patients had died, out of which 50 deaths were for cardiovascular reasons. Continuous NTproBNP and ST2 were both significantly associated with all-cause mortality (1.0001; 1.00001–1.0002, p?=?0.04 and 1.03; 1.003–1.06, p?=?0.03), NTproBNP but not ST2 remained significant for cardiovascular mortality after adjustments (1.0001; 1.00001–1.0002, p?=?0.03 and 1.01; 0.77–1.06, p?=?0.53), respectively. NTproBNP above median (>328?ng/L) compared to below median was significantly associated with all-cause mortality(HR: 4.0; CI :2.46–6.61; p?p?Conclusion: In elderly patients with symptoms of heart failure ST2 was not superior to NTproBNP to predict all cause or cardiovascular mortality. Furthermore, it is unclear if the combination of ST2 and NTproBNP will improve long-term prognostication beyond what is achieved by NTproBNP alone.     

血清Irisin水平与心衰的相关性研究

目的:观察心衰患者血清IRISIN水平变化规律,研究Irisin对心衰诊疗的临床价值。方法:连续收集西京医院心内科住院的心衰患者132例,根据NYHA心功能分级将患者分为三组,其中心功能Ⅱ级48例,Ⅲ级44例,Ⅳ级40例,同时选取心功能正常(左室射血分数LVEF50%)的30例健康体检者为对照组。采用酶联免疫吸附试验(ELISA)检测患者血清中Irisin水平,根据Irisin水平分为低Irisin组和高Irisin组,比较两组间心衰的发生率,分析Irisin水平与心衰的关系。结果:①心衰组Irisin水平显著低于心功能正常组(6790±3628 ng/mL vs 12691±2272 ng/mL,P0.01),且从Ⅱ级到Ⅳ级,逐渐降低;②心衰组LVEF值显著低于心功能正常组(45.7±8 vs 59.7±4.3,P0.01),且从Ⅱ级到Ⅳ级,逐渐降低;③心衰组N末端B型利钠肽原(ProBNP)水平显著高于心功能正常组(2938±2795 pg/mL vs 184±151 pg/mL,P0.01),且从Ⅱ级到Ⅳ级,逐渐升高;④低Irisin组心衰发生率明显高于高Irisin组(92.6%vs47.5%,P0.01);⑤单因素相关分析显示:血清Irisin水平与左室射血分数呈正相关(r=0.694,P0.05),与proBNP呈负相关(r=-0.45,P0.05);结论:心衰患者血清Irisin水平降低,而且随着心功能的恶化显著降低,心衰患者血清Irisin水平与心衰程度有一定的相关性。     

血液透析联合血液灌流治疗对慢性肾衰竭患者肾功能、微炎症状态和血液净化效果的影响

目的:探讨血液透析(HD)联合血液灌流(HP)治疗对慢性肾衰竭(CRF)患者肾功能、微炎症状态和血液净化效果的影响。方法:选取2015年3月-2017年3月期间我院收治的CRF患者90例作为研究对象,采用随机数字表法分为对照组(n=45)和研究组(n=45),对照组在常规治疗的基础上给予HD治疗,研究组在对照组治疗的基础上给予HD联合HP治疗,对比两组治疗前后的肾功能、微炎症状态、血液净化效果。结果:治疗后研究组肌酐清除率(Ccr)较对照组增加,血尿氮(BUN)、血肌酐(Cr)较对照组下降(P0.05)。治疗后研究组白细胞介素(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平较对照组下降(P0.05)。治疗后研究组同型半胱氨酸(Hcy)、甲状旁腺激素(PTH)及β2-微球蛋白(β2-MG)水平较对照组下降(P0.05)。研究组总不良反应发生率为4.44%(2/45),低于对照组的15.56%(7/45)(P0.05)。结论:HD联合HP治疗CRF,能够有效改善患者肾功能和炎症反应,清除肾脏内的有毒物质,从而提升血液净化效果,且安全性较好。